Two biotech stocks make perfect candidates for this sort of strategy right now. Let's take a close look at these two biotech ...

Analysts estimate that Oncolytics Biotech will report an earnings per share (EPS) of $-0.09. Investors in Oncolytics Biotech ...

Amid a shaky macroeconomic backdrop, biotech stocks have underperformed, with XBI showing poor technical momentum and ...

ADAPTIVE BIOTECH ($ADPT) posted quarterly earnings results on Thursday, May 1st. The company reported earnings of -$0.20 per share, beating estimates of -$0.30 by $0. ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...

Trump’s tariffs and the global trade war continue to impact global markets. Follow along for live updates on the Dow, S&P 500 and Nasdaq.

Anbio Biotechnology’s NNNN share price has surged by 5.23%, which has investors questioning if this is right time to sell.

Two biotech stocks make perfect candidates for this sort ... Now Vertex is shifting its Trikafta patients to Alyftrek. In its recent earnings call, the company said the launch of this product ...